Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Videos

Belantamab Mafodotin Plus Bortezomib and Dexamethasone for Relapsed/Refractory MM

 

Robert Rifkin, MD, Rocky Mountain Cancer Center, Denver, Colorado, discusses the ongoing, phase 3 DREAMM-7 study exploring belatanmab mafodotin  in combination with bortezomib and dexamethasone for patients with relapsed/refractory multiple myeloma (MM).

This study was presented at the virtual 62nd ASH Annual Meeting and Exposition.


Advertisement

Advertisement

Advertisement